Biofrontera Inc.NASDAQ: BFRI

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Jan 8, 2025 · Issued by Biofrontera Inc.

Last patient completed 1 year follow-up of study ALA-BCC-CT013 in December 2024.
Data from follow-up will be included in FDA submission, expected in Q3 2025.
Biofrontera announced highly statistically significant results for all primary and secondary endpoints (p